HBIO
Price
$0.77
Change
-$0.01 (-1.30%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
184.01M
Earnings call today
NEOG
Price
$9.88
Change
-$0.10 (-1.00%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
3.42B
20 days until earnings call
Ad is loading...

HBIO vs NEOG

Header iconHBIO vs NEOG Comparison
Open Charts HBIO vs NEOGBanner chart's image
Harvard Bioscience
Price$0.77
Change-$0.01 (-1.30%)
Volume$1.89K
Capitalization184.01M
Neogen
Price$9.88
Change-$0.10 (-1.00%)
Volume$57.51K
Capitalization3.42B
HBIO vs NEOG Comparison Chart
Loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NEOG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HBIO vs. NEOG commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HBIO is a Hold and NEOG is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (HBIO: $0.78 vs. NEOG: $9.98)
Brand notoriety: HBIO and NEOG are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: HBIO: 67% vs. NEOG: 137%
Market capitalization -- HBIO: $184.01M vs. NEOG: $3.42B
HBIO [@Medical Specialties] is valued at $184.01M. NEOG’s [@Medical Specialties] market capitalization is $3.42B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HBIO’s FA Score shows that 1 FA rating(s) are green whileNEOG’s FA Score has 1 green FA rating(s).

  • HBIO’s FA Score: 1 green, 4 red.
  • NEOG’s FA Score: 1 green, 4 red.
According to our system of comparison, both HBIO and NEOG are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HBIO’s TA Score shows that 4 TA indicator(s) are bullish while NEOG’s TA Score has 4 bullish TA indicator(s).

  • HBIO’s TA Score: 4 bullish, 2 bearish.
  • NEOG’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, HBIO is a better buy in the short-term than NEOG.

Price Growth

HBIO (@Medical Specialties) experienced а -5.27% price change this week, while NEOG (@Medical Specialties) price change was +6.06% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.36%. For the same industry, the average monthly price growth was -7.35%, and the average quarterly price growth was -3.83%.

Reported Earning Dates

HBIO is expected to report earnings on May 13, 2025.

NEOG is expected to report earnings on Jul 29, 2025.

Industries' Descriptions

@Medical Specialties (-1.36% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NEOG($3.42B) has a higher market cap than HBIO($184M). NEOG YTD gains are higher at: -17.792 vs. HBIO (-63.185). NEOG has higher annual earnings (EBITDA): 189M vs. HBIO (8.03M). NEOG has more cash in the bank: 230M vs. HBIO (4.28M). HBIO has less debt than NEOG: HBIO (42.8M) vs NEOG (889M). NEOG has higher revenues than HBIO: NEOG (919M) vs HBIO (112M).
HBIONEOGHBIO / NEOG
Capitalization184M3.42B5%
EBITDA8.03M189M4%
Gain YTD-63.185-17.792355%
P/E RatioN/A150.80-
Revenue112M919M12%
Total Cash4.28M230M2%
Total Debt42.8M889M5%
FUNDAMENTALS RATINGS
HBIO vs NEOG: Fundamental Ratings
HBIO
NEOG
OUTLOOK RATING
1..100
5054
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
96
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9090
PRICE GROWTH RATING
1..100
9798
P/E GROWTH RATING
1..100
22
SEASONALITY SCORE
1..100
32n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NEOG's Valuation (96) in the Medical Specialties industry is in the same range as HBIO (99) in the Biotechnology industry. This means that NEOG’s stock grew similarly to HBIO’s over the last 12 months.

NEOG's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as HBIO (100) in the Biotechnology industry. This means that NEOG’s stock grew similarly to HBIO’s over the last 12 months.

NEOG's SMR Rating (90) in the Medical Specialties industry is in the same range as HBIO (90) in the Biotechnology industry. This means that NEOG’s stock grew similarly to HBIO’s over the last 12 months.

HBIO's Price Growth Rating (97) in the Biotechnology industry is in the same range as NEOG (98) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to NEOG’s over the last 12 months.

HBIO's P/E Growth Rating (2) in the Biotechnology industry is in the same range as NEOG (2) in the Medical Specialties industry. This means that HBIO’s stock grew similarly to NEOG’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HBIONEOG
RSI
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
52%
Stochastic
ODDS (%)
N/A
Bearish Trend 2 days ago
73%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 6 days ago
73%
Bullish Trend 5 days ago
67%
Declines
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 9 days ago
76%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
57%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
83%
View a ticker or compare two or three
Ad is loading...
HBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NEOG
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RGGYX24.09N/A
N/A
Victory RS Global Y
RBCIX10.27N/A
N/A
RBC China Equity I
TGDVX15.72N/A
N/A
TCW Relative Value Large Cap N
FDSCX34.67N/A
N/A
Fidelity Stock Selector Small Cap
NELIX58.85N/A
N/A
Nuveen Equity Long/Short I

HBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, HBIO has been loosely correlated with SGHT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if HBIO jumps, then SGHT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HBIO
1D Price
Change %
HBIO100%
-5.12%
SGHT - HBIO
46%
Loosely correlated
+3.81%
ICUI - HBIO
42%
Loosely correlated
-8.40%
XRAY - HBIO
41%
Loosely correlated
-1.53%
CTKB - HBIO
39%
Loosely correlated
-3.75%
NEO - HBIO
39%
Loosely correlated
-10.00%
More

NEOG and

Correlation & Price change

A.I.dvisor indicates that over the last year, NEOG has been loosely correlated with CRL. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if NEOG jumps, then CRL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NEOG
1D Price
Change %
NEOG100%
-4.04%
CRL - NEOG
45%
Loosely correlated
-0.45%
RVTY - NEOG
42%
Loosely correlated
+0.57%
IQV - NEOG
40%
Loosely correlated
-1.49%
HBIO - NEOG
39%
Loosely correlated
-5.12%
ICUI - NEOG
39%
Loosely correlated
-8.40%
More